Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE-CMD: Empagliflozin for Coronary Microvascular Dysfunction
NCT07533747Phase 3Not yet recruiting
- Sponsor
- King's College London
- Start
- May 2026
- Primary completion
- May 2031
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of empagliflozin in Coronary Microvascular Dysfunction (CMD), sponsored by King's College London. Primary endpoint: Myocardial Perfusion Reserve at 8 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT07533747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533747.